Clinical Trial Update: A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update on the investigational drug GLPG5101 (19CP02) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, with the study currently no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• GLPG5101 (GLPG5101)

Snippet

Sponsor: Galapagos NV | Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING